T. Rowe Price Associates’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $22K | Hold |
|
|||||
|
2024
Q4 | $89K | Sell |
|
|||||
|
2024
Q3 | $188K | Hold |
|
|||||
|
2024
Q2 | $200K | Buy |
|
|||||
|
2024
Q1 | $359K | Buy |
|
|||||
|
2023
Q4 | $174K | Sell |
|
|||||
|
2023
Q3 | $111K | Sell |
|
|||||
|
2023
Q2 | $394K | Sell |
|
|||||
|
2023
Q1 | $500K | Buy |
|
|||||
|
2022
Q4 | $707K | Buy |
|
|||||
|
2022
Q3 | $758K | Sell |
|
|||||
|
2022
Q2 | $646K | Buy |
|
|||||
|
2022
Q1 | $551K | Buy |
|
|||||
|
2021
Q4 | $712K | Sell |
|
|||||
|
2021
Q3 | $9.25M | Sell |
|
|||||
|
2021
Q2 | $31.5M | Sell |
|
|||||
|
2021
Q1 | $48.1M | Sell |
|
|||||
|
2020
Q4 | $87.9M | Buy |
|
|||||
|
2020
Q3 | $34M | Buy |
|
|||||
|
2020
Q2 | $17.4M | Buy |
|